VANCOUVER, BC–(Jun 28, 2016) – Breathtec BioMedical, Inc is holding a press conference today to announce plans for the commencement of the company’s clinical trial program at Innovation Boulevard located in Surrey, British Columbia.
Today’s announcement marks the beginning of an intensive research review into NA-NOSE, an advanced stage, nanotechnology-based breath analysis device from the Technion – Israel Institute of Technology which has been in-licensed by Breathtec. The system has been developed to detect the volatile biomarkers of diseases from exhaled breath, and Breathtec has chosen the Province of British Columbia and the City of Surrey to hold its clinical trials for selected respiratory infections at the Health & Technology District on Innovation Boulevard.
Breathtec Biomedical, Inc. (“Breathtec”) was formed to propel innovative research in the area of breath analysis as a medical screening tool. Our efforts are aimed at leading the development of commercially viable methods for the early screening of diseases such as lung & breast cancers, neurodegenerative diseases (eg: Alzheimer’s / Parkinson’s), tuberculosis, diabetes, liver disease and more.
Image source: Breathtec BioMedical